Vigil Neuroscience (NASDAQ:VIGL) Receives “Buy” Rating from Guggenheim

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating restated by stock analysts at Guggenheim in a research note issued on Friday,Benzinga reports.

A number of other equities analysts have also recently commented on VIGL. William Blair started coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. Wedbush lifted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Thursday. Finally, JMP Securities restated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $19.75.

Vigil Neuroscience Stock Up 6.1 %

Shares of Vigil Neuroscience stock traded up $0.14 during trading on Friday, reaching $2.49. The company’s stock had a trading volume of 1,836,336 shares, compared to its average volume of 3,136,496. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06. The firm’s 50-day moving average is $2.12 and its two-hundred day moving average is $3.12. The company has a market cap of $101.91 million, a price-to-earnings ratio of -1.20 and a beta of 1.76.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. On average, equities research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vigil Neuroscience in the 2nd quarter worth about $87,000. Renaissance Technologies LLC increased its position in Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after buying an additional 11,536 shares in the last quarter. Walleye Capital LLC raised its stake in Vigil Neuroscience by 334.4% during the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after buying an additional 92,217 shares during the last quarter. Verition Fund Management LLC bought a new stake in Vigil Neuroscience in the third quarter worth $442,000. Finally, Geode Capital Management LLC grew its stake in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after acquiring an additional 66,712 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.